{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["10(6)"],"submitter":["Zhang X"],"pubmed_abstract":["<h4>Background</h4>Biomarkers are a key tool in early detection, prognostication, survival, and predicting treatment response of colorectal cancer (CRC). However, little is known about biomarker testing for CRC patients in real-life clinical practice in China. This study aimed to address the usage of biomarker testing and analyze factors related to its acceptance among Chinese patients with advanced CRC.<h4>Methods</h4>A multicenter, cross-sectional, hospital-based clinical epidemiology study was conducted from March 2020 to March 2021. Nineteen hospitals were selected in seven geographical regions of China using stratified, multistage, nonrandomized cluster sampling. Data on demographics and clinical characteristics of each eligible CRC patient in stage III or IV diseases were recorded ba"],"journal":["Annals of translational medicine"],"pagination":["324"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9011275"],"repository":["biostudies-literature"],"pubmed_title":["Utilization of genetic biomarkers testing and its associated factors in advanced colorectal cancer patients in China: a nationwide multicenter clinical epidemiological study."],"pmcid":["PMC9011275"],"pubmed_authors":["Qiao YL","Lian XM","Ma L","Liu YY","Cao J","Shi JH","Yu YQ","Xu HF","Wang XH","Li L","Zhao YQ","Huang JX","Liu Y","Wang WJ","Feng CY","Du LB","Zhang X","Fan YP","Zhang SK","Du JC","China Working Group on Colorectal Cancer Survey","Gu XF","Duan SX"],"additional_accession":[]},"is_claimable":false,"name":"Utilization of genetic biomarkers testing and its associated factors in advanced colorectal cancer patients in China: a nationwide multicenter clinical epidemiological study.","description":"<h4>Background</h4>Biomarkers are a key tool in early detection, prognostication, survival, and predicting treatment response of colorectal cancer (CRC). However, little is known about biomarker testing for CRC patients in real-life clinical practice in China. This study aimed to address the usage of biomarker testing and analyze factors related to its acceptance among Chinese patients with advanced CRC.<h4>Methods</h4>A multicenter, cross-sectional, hospital-based clinical epidemiology study was conducted from March 2020 to March 2021. Nineteen hospitals were selected in seven geographical regions of China using stratified, multistage, nonrandomized cluster sampling. Data on demographics and clinical characteristics of each eligible CRC patient in stage III or IV diseases were recorded ba","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Mar","modification":"2026-06-05T05:59:48.221Z","creation":"2025-04-05T23:59:47.092Z"},"accession":"S-EPMC9011275","cross_references":{"pubmed":["35434030"],"doi":["10.21037/atm-22-988"]}}